Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499667 | 1.00 | NOTUM (0.36) | NOTUMDRD2ALDH1A1MAPTLMNA | |
| SCHEMBL499399 | 0.87 | CYP1A2 (0.39) | NOTUMDRD2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL499398 | 0.87 | CYP1A2 (0.39) | NOTUMDRD2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL499646 | 0.86 | ALDH1A1 (0.37) | DRD2ALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL499849 | 0.84 | ALDH1A1 (0.37) | NOTUMDRD2ALDH1A1MAPTLMNA | |
| SCHEMBL499850 | 0.84 | ALDH1A1 (0.37) | NOTUMDRD2ALDH1A1MAPTLMNA | |
| SCHEMBL4568001 | 0.82 | MAPT (0.51) | NOTUMDRD2ALDH1A1MAPTPOLB | |
| SCHEMBL499384 | 0.82 | DRD2 (0.42) | NOTUMDRD2ALDH1A1MAPTLMNA | |
| SCHEMBL499479 | 0.81 | ALDH1A1 (0.39) | NOTUMDRD2ALDH1A1MAPTKMT2A | |
| SCHEMBL499461 | 0.81 | CTSL (0.39) | NOTUMDRD2ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163016-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-06-12 | — | — | US | disclosed |
| US-8106043-B2 | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| US-20100009975-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009975-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | NOTUM 1569/4885DRD2 3033/4885ALDH1A1 861/4885 |
| US-20140163016-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | NOTUM 1569/4885DRD2 3033/4885ALDH1A1 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.